bluuebunny/crossref_metadata_2025_split huggingface dataset:
Stereotactic external beam irradiation in previously untreated brain tumors in children and adolescents
Authors: Freeman Carolyn R. , Souhami Luis , Caron Jean‐Louis , Villemure Jean‐Guy , Olivier André , Montes José , Farmer Jean‐Pierre , Podgorsak Ervin B. 
Published: February 2007

AbstractStereotactically guided external beam irradiation may be a useful form of treatment for small, well‐circumscribed, but surgically inaccessible, primary brain tumors that are either benign or of low malignant potential. Between March 1988 and December 1991, 10 children and adolescents with previously untreated primary brain tumors were treated with stereotactic external beam irradiation (SEBI) using a linac‐based dynamic technique. Eleven lesions were treated in the 10 patients. Treatment was given using a collimator diameter of 1.5‐4 cm (median 2 cm). Single fractions of 18, 20, and 25 Gy were used for 3 lesions in 2 patients. A fractionated schedule delivering a median dose of 42 Gy in 6 fractions over 2 weeks was used in the remaining 8 patients. Morbidity related to treatment was minimal. Three patients suffered a temporary worsening of preexisting neurological symptoms and/or signs at 2, 5, and 5 months posttreatment, with subsequent recovery in all. With a median follow up post‐SEBI of 17.5 months (range 5‐47 months), improvement in neurological findings related to the lesion was noted for 5 treated lesions; 6 remained clinically stable. Seven of the 11 treated lesions improved radiologically, and only 2 showed evidence of progressive disease. Stereotactic external beam irradiation represents a potentially valuable therapeutic option for selected primary brain tumors in the pediatric and adolescent age group. Morbidity related to the treatment appears acceptable in frequency and type, and preliminary data with regard to response are encouraging. However, in order to assess the impact of such treatment on long‐term tumor control and survival, further experience with a larger cohort of patients followed for a longer period of time will be necessary. © 1994 Wiley‐Liss, Inc.
Plasma and urine levels of methotrexate and 7‐hydroxymethotrexate in children with all during maintenance therapy with weekly oral methotrexate
Authors: Skoglund Kathleen A. , Söderhäll Stefan , Beck Olof , Peterson Curt , Wennberg Mona , Hayder Salah , Björk Olle 
Published: February 2007

AbstractA new high‐performance liquid chromatographic assay was used to determine methotrexate (MTX) and its main metabolite, 7‐hydroxymethotrexate (7‐OH‐MTX), in the plasma (n ‐ 17) and urine (n = 14) of children (age 3‐12 years) on maintenance therapy for acute lymphocytic leukemia (n = 14) or non‐Hodgkin's lymphoma (n = 3). Each child received oral doses of weekly MTX (4.0‐29 mg/m2) and daily 6‐mer‐captopurine (40‐111 mg/m2). Plasma samples were collected daily from two children during the 1‐week dose interval. A limited sampling strategy was designed, whereby 2 days of blood sampling were used in the other 15 patients. Morning urine samples were collected daily for 1 week following MTX intake from 14 of the children. MTX was detectable in all plasma and urine samples for the entire dose interval. The main metabolite, 7‐OH‐MTX, could be detected in plasma and urine from all patients on the first day after dose intake but only in a few patients during the whole dose interval. Interpatient variability of MTX and 7‐OH‐MTX levels was high at all points during the week. Significant correlation were found between the urinary MTX levels on days 2 and 7 and plasma MTX levels on day 2 after intake. No significant correlation was found between drug levels in plasma or urine and liver function tests in the children showing signs of mild liver injury. This assay provides a tool for further studies on the role of pharmacokinetics for the clinical effects of weekly oral low‐dose MTX given alone or in combination with 6‐mercaptopurine. © 1994 Wiley‐Liss, Inc.
Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: The state of the art
Authors: Pieters Rob , Kaspers Gertjan J. L. , Klumper Edwin , Veerman Anjo J.P. 
Published: February 2007

AbstractNowadays about two‐thirds of children with acute lymphoblastic leukemia (ALL) can be cured with chemotherapy, but one‐third die from the disease. The clinical response of leukemic cells to chemotherapy is roughly due to two factors: the effective drug levels reaching the cells and the resistance of these cells to the drugs. The clinical value of cellular drug resistance in children with ALL is not known. We developed an in vitro assay to study drug resistance in these children. In this article, the main results obtained with this MTT assay on samples from 137 children with ALL are summarized: (1) patients whose cells are resistant to several drugs at initial diagnosis have a poor prognosis; (2) relapsed leukemias show a considerable drug resistance which might partly explain the poor prognosis. Relapsed cases differ in their type and degree of resistance; (3) the poor outcome of high risk groups as defined by age and immunophenotype can partly be explained by specific patterns of drug resistance; (4) P‐glycoprotein‐mediated multidrug resistance is not an important cause of resistance in childhood ALL; and (5) no relation exists between the activities of the purine enzymes HGPRT, 5′NT, ADA, and PNP and drug resistance in childhood ALL. The conclusion is that in vitro drug resistance data have clinical relevance and can be used to develop more effective and less toxic treatment strategies in childhood ALL. © 1994 Wiley‐Liss, Inc.
Predisposition to corynebacterium jeikeium infection in acute lymphoblastic leukemia: a report of two cases in trinidad
Authors: Fosi‐Mbantenkhu Joseph , Orett F. A. 
Published: February 2007

AbstractTwo hospitalized patients (a 4 and 6 year old male and female, respectively) with acute lymphoblastic leukaemia (ALL), had each at different periods sustained burns with necrosis from extravasation of chemo‐therapeutic products. Pure cultures from their wound exudates and blood repeatedly revealed Corynebacterium jeikeium, an organism recognized and identified in the last decade as an opportunistic cause of life‐threatening nosocomial infections particularly in patients on long‐term multiple antimicrobial therapy, and in those who are neutropenic or have cardiac valve replacement. The organism has been found to be highly resistant to many antibiotics but sensitive to a few, including vancomycin. Both patients were successfully treated with vancomycin and are reviewed here to emphasize the importance of this group of microorganisms resistant to multiple antibiotic therapy as possible frequent cause of sub‐acute bacterial infection in immunode‐pressed conditions such as ALL, especially when external wounds are inflicted by extravasation of antileukaemic agents (notably, vinca alkaloids). A review of the literature indicates that these are the first reported cases of infection caused by these organisms in Trinidad, and it is of clinical and therapeutic interest to note that they are sensitive to norfloxacin, polymyxin, tetracycline, and particularly vancomycin in this Study. © 1994 Wiley‐Liss, Inc.
The role of fast neutron therapy in unresectable pelvic osteosarcoma: preliminary report
Authors: Carrie C. , Breteau N. , Negrier S. , Frappaz D. , Bouffet E. , Thiesse P. H. , Blay J. Y. , Clavel M. , Philip T. , Biron P. , Brunat‐Mentigny M. 
Published: February 2007

AbstractPrimary osteosarcoma of the pelvic bones represents less than 10% of all osteosarcoma. despite mutilating surgical procedures or high‐dose radiotherapy and neoadjuvant chemotherapy, local failures and distant metastases remain common. the 2‐year actuarial survival rate is less than 50% and the disease‐free survival is under 20% at 2 years. we report 4 cases of pelvic osteosarcoma treated by a combination of chemotherapy, photon beam and neutron beam radiotherapy. after a median follow‐up of 24 months, all 4 patients are alive and disease free. © 1994 wiley‐liss, inc.
Treatment of relapsing acute lymphoblastic leukemia in childhood. III. Experiences with 54 first bone marrow, nine isolated testicular, and eight isolated central nervous system relapses observed 1985‐1989
Authors: Weid Nicolas Von Der , Wagner Bendicht , Angst Regula , Arnet Beat , Baumgartner Christoph , Beck Daniel , Bleher Arnold , Caflisch Ueli , Delaleu Beatrice , Feldges Andreas , Frey Eva , Glanzmann Ingeborg , Hirt Andreas , Imbach Paul , Kratel Silke , Küchler Henri , Leibundgut Kurt , Meister Andreas , Morin Anne‐Marie , Nobile Luisa , Plüss Hans‐Juerg , Lüthy Annette Ridolfi , Signer Erich , Stettler Erich , Wyss Marinette , Wagner Hans‐Peter 
Published: February 2007

AbstractOf 54 children with acute lymphoblastic leukemia (ALL) and first hematological recurrence observed between 1985 and 1989, 31 relapsed while still on treatment and 23 after cessation of therapy. Of the former, only one survived. Of the latter, 11 children survived after a minimum follow‐up of 25 months. During the same period, a first isolated testicular relapse was observed in nine boys, of whom six survived, and an isolated CNS relapse in eight patients, of whom three survived. As a rule, survivors of a bone marrow or testicular relapse were doing well while those surviving a CNS relapse had considerable neuropsychological sequelae. These results, compared with those of two preceding studies, suggest that with intensification of front‐line treatments, it becomes more difficult to rescue children who relapse, particularily those with a bone marrow relapse while on therapy. © 1994 Wiley‐Liss, Inc.
Cerebral irradiation causes blunted pubertal growth in girls treated for acute leukemia
Authors: Moëll C. , Marky I. , Hovi L. , Kristinsson J. , Rix M. , Moe P. J. , Garwicz S. 
Published: February 2007

AbstractThe improved treatment of childhood leukemia is a major achievement. The late effects of the treatment need further investigation. Growth inhibition has been demonstrated in earlier studies.Growth and the timing of puberty were studied in 179 girls who had been treated for acute lymphoblastic leukemia (ALL) in Denmark, Finland, Norway, and Sweden. The patients were divided into two groups according to mode of CNS prophylaxis: with or without cerebral irradiation.Longitudinal analysis of 103 patients showed no difference in prepubertal growth in irradiated and nonirradiated girls. Growth during puberty was normal in girls without irradiation and below normal in irradiated girls. There was no difference in growth between girls after 24 Gy or 20 Gy of cerebral irradiation. Irradiated girls had a final height which was one SD less than expected before puberty and menarche occurred one year earlier than in the nonirradiated girls.Prophylactic cerebral irradiation is the most important factor for subnormal growth after treatment for ALL. There is no short‐term influence on growth but the effects of irradiation become apparent several years after therapy when girls enter puberty somewhat early and have a subnormal pubertal growth. Growth and growth hormone (GH) levels should be evaluated several years after CNS irradiation, and treatment with GH and/or luteinizing hormone releasing hormone (LHRH) analogues may be considered. © 1994 Wiley‐Liss, Inc.
Somatostatin therapy in l‐asparaginase‐induced pancreatitis
Authors: Cheung Y. F. , Lee C. W. , Chan C. F. , Chan K. L. , Lau Y. L. , Yeung C. Y. 
Published: February 2007

AbstractL‐Asparaginase‐induced pancreatitis is an uncommon but potentially lethal complication. An 8‐year‐old girl with acute lymphoblastic leukaemia developed acute pancreatitis following treatment with asparaginase. Clinical and laboratory improvements were evident after treatment with somatostatin, with no complications of pancreatitis. Induction therapy for the leukaemia was able to be continued and complete remission was documented during the course of pancreatitis and somatostatin treatment, suggesting a beneficial role of somatostatin in the management of asparaginase‐induced pancreatitis. © 1994 Wiley‐Liss, inc.
Leukemic ophthalmopathy: A report of 21 pediatric cases
Authors: Curto M. Lo , D'Angelo P. , Lumia F. , Provenzano G. , Zingone A. , Bachelot C. , Bagnulo S. , Behrendt H. , Jankovic M. , Masera G. , Mann J. , Rosito P. , Schaison G. , Schuler D. 
Published: February 2007

AbstractA multicentric retrospective study on leukemic ophthalmopathy (LO) is reported. It includes 21 patients, 16 males and 5 females, with acute leukemia (AL) observed in 10 SIOP centers. LO developed in three patients at the time of diagnosis of AL; five patients were in first complete remission (three off therapy); four patients were in second or third remission; and nine were in combined relapse. Most frequent symptoms were blurred vision, photophobia, and ocular pain. Two patients with acute nonlymphoblastic leukemia died before treatment; another underwent bone marrow transplantation; one patient with B‐cell acute lymphoblastic leukemia (B‐ALL) treated with chemotherapy and radiotherapy died 4 months after LO; the remaining 17 children were treated according to different schedules with (10) or without (7) radiotherapy on the affected eye. Twelve patients achieved ocular remission and four of these had a second ocular relapse. Complete remission after LO treatment lasting for more than 3, 7, 24, 29 months was observed in four patients. The authors conclude that cure is possible in patients who had LO in first complete remission treated with chemotherapy and radiotherapy at high dose on the affected eye. © 1994 Wiley‐Liss, Inc.
Renal cell carcinoma in children: A single institution's experience
Authors: Eckschlager Tomáš , Kodet Roman 
Published: February 2007

AbstractSeven patients with renal cell carcinomas (RCC) were treated at the Department of Pediatric Oncology in Prague over a period of 15 years. The average age at diagnosis was 8 years 9 months. Histology review showed five tumors to be of clear cell type with mixed tubular, papillary, and solid patterns; one tumor was purely papillary, eosinophilic type and one was composed of clear and eosinophilic cells. Five patients received chemotherapy and four of them also received radiotherapy. Four patients are without evidence of disease with a minimal follow‐up period of 2 years. These four were all clinical stage I or II. Two stage III patients died of metastatic disease. One patient died of tumor emboli to the lungs at operation. Tumor diagnosis and treatment of the patients in the lower clinical stages seem to have a favorable prognostic impact in childhood RCC. Combined chemotherapy with vinblastine as one of the agents, and possibly additional immunotherapy, appears to have promising results, although the number of patients treated thus far is limited. © Wiley‐Liss, Inc.
Granular cell tumor of the biliary system
Authors: Mackenzie Douglas J. , Klapper Ellen , Gordon Leo A. , Silberman Allan W. 
Published: February 2007

AbstractGranular cell tumors (GCT) are rare benign neoplasms of Schwann cell origin which have been found in virtually every location in the body. Their location in the biliary system is unusual, and typically occurs in black females during the fourth decade of life. Forty‐eight cases have been reported since 1952. We present two patients treated for obstructive jaundice caused by GCT of the extrahepatic biliary tree. The literature on biliary GCT is reviewed and their management is outlined. Local excision with Roux‐y‐hepaticojejunostomy was performed in one patient with GCT obstructing the common bile duct at the level of the cystic duct. Pancreaticoduodenectomy was performed on one patient for GCT of the common bile duct involving the ampulla and adjacent pancreas. GCT of the extrahepatic biliary system are rare but should be considered in black females who present with obstructive jaundice in the fourth decade of life. Local excision with cholecystectomy and reconstruction of the biliary remnant is indicated. Primary biliary anastomosis is desired but choledochojejunostomy or hepaticojejunostomy may be necessary. Rarely, pancreaticoduodenectomy may be indicated in GCT of the distal common bile duct. © 1994 Wiley‐Liss, Inc.
Synovial sarcoma of the larynx in a child: Case report and histological appearances
Authors: Morland Bruce , Cox Graham , Randall Chris , Ramsay Alan , Radford Martin 
Published: February 2007

AbstractSynovial sarcoma of the larynx is extremely rare having been reported only six times previously in the literature. We add another case report, which to our knowledge is the first recorded case in a child. We discuss the alternative approach of combination chemotherapy and radiotherapy which in this case led to a remission lasting about 3 years. The immunohistological and ultrastructural characteristics of the tumour are also presented. © 1994 Wiley‐Liss, Inc.
Acute leukemia in association with langerhans cell histiocytosis
Authors: Egeler R. Maarten , Neglia Joseph P. , Aricò Maurizio , Favara Blaise E. , Heitger Andreas , Nesbit Mark E. 
Published: February 2007

AbstractLangerhans cell histiocytosis (LCH) and malignancy occurring in the same individual is unusual and has generally been the subject of isolated case reports. To better define the occurrence of these events a registry of cases with synchronous or asynchronous LCH and malignancy was developed with the cooperation of the Histiocyte Society.In 1991 the Histiocyte Society surveyed its members requesting information on cases in which LCH was associated with malignancy. The questionnaire was mailed to all members of the society and specifically requested information on the clinical and laboratory features of the cases, disease evolution, and response to therapy. Retrospective reporting was allowed. With this initial data, an ongoing registry of LCH patients with associated malignancy was begun of such cases, including evolution and response to therapy.Twenty‐seven patients were enrolled during the first year of the registry, of whom 4 patients had the association of LCH with a malignant lymphoma and 10 cases had an association of LCH with other types of solid tumor. The remaining 13 patients had the association of LCH with acute leukemia. In five cases, LCH was associated with acute lymphoblastic leukemia FAB L1 (ALL). In four cases the ALL preceded the LCH by 6 months to 1 year. In four of five patients the LCH was localized; in two instances the LCH was treated with chemotherapy. In all cases the leukemia was treated according to local standard ALL protocols and in one case autologous bone marrow transplantation (ABMT) was performed at relapse. Three patients are free of leukemia, one of whom has persistent localized LCH of the skin. Two patients died of the ALL, one of whom was free of the LCH at the time of death. In eight instances LCH was reported in association with acute myeloid leukemia (AML). Six of these patients had a generalized form of LCH. In seven the diagnosis of LCH preceded the diagnosis of leukemia by more than 2 years (median 4 years). In the remaining patient both diagnoses were made concurrently. In all seven cases in whom LCH was the initial diagnosis the treatment consisted of chemotherapy and/or radiotherapy. Seven patients died from the AML, five without evidence of LCH.The temporal patterns of the LCH‐ALL and LCH‐AML associations are distinct with ALL usually preceding the diagnosis of LCH and AML succeeding it. Such a pattern is suggestive that in cases of ALL the LCH may be a reactive process while in cases of AML occurring after LCH the primary LCH therapy may play an inductive role in the leukemia. © 1994 Wiley‐Liss, Inc.
Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low‐dose etoposide on intergroup rhabdomyosarcoma study III: An interim report
Authors: Heyn Ruth , Khan Fareed , Ensign Lisa G. , Donaldson Sarah S. , Ruymann Frederick , Smith Malcolm A. , Vietti Teresa , Maurer Harold M. 
Published: February 2007

AbstractThe early occurrence of five cases of acute myeloid leukemia (AML) in children treated for primary rhabdomyosarcoma on the Intergroup Rhabdomyosarcoma Study III (IRS III) has prompted this report. These patients received cyclophosphamide and four received etoposide in addition to other agents.There were 1,062 eligible patients entered on IRS III between 1984 and 1991. Following surgery, treatment consisted of multiagent chemotherapy and radiotherapy in select clinical groups. Median follow‐up time is 3.7 years (range 0–7.4 years). Incidence densities and odds ratios for AML were calculated for various treatment groups.Five cases of secondary AML have been reported through August 1992. A single case of osteogenic sarcoma was reported in the same period and a patient with myelodys plastic syndrome has occurred since that time. Median time to development of AML was 39 months. Incidence density of AML for patients receiving neither cyclophosphamide nor etoposide was 0, for those receiving cyclophosphamide but no etoposide it was 7.6, and when both agents were given, it was 51.6. The odds ratios of AML for the latter two groups indicated a risk of AML which was seven times higher in the patients who received both agents. A history of breast cancer was present in all five families of patients with AML and several other cancers had occurred in three families.Preliminary analysis suggests a possible causal role for low‐dose etoposide in addition to that assumed for cyclophosphamide in the early development of AML among pediatric patients treated for rhabdomyosarcoma. © 1994 Wiley‐Liss, Inc.
Negative 123‐meta‐lodobenzyl‐guanidine imaging in Ewing's sarcoma of bone
Authors: Oberlin O. , Lumbroso J. , Terrier P. H. , Hartmann O. , Lemerle J. , Parmentier C. 
Published: February 2007

AbstractThe role of radiolabeled meta‐iodobenzyl‐guanidine (mlBC) is established in the detection and the staging of neuroblastoma. We designed a study of mlBG scanning for patients with Ewing's sarcoma, a tumor for which a neuroectodermic origin has been proposed.We explored 15 children with round cell sarcoma of bone by a whole body scan carried out 24 hours after injection of 123‐1 mlBG. No patient demonstrated significant uptake either at the site of the primary or at the sites of metastases.These results suggest that despite its neural histogenesis Ewing's sarcoma is a member of the nonneuroblastoma neural crest tumors, which does not produce or store adrenergic metabolites. © 1994 Wiley‐Liss, Inc.
Primary cardiac angiosarcoma: A case report and review of therapeutic options
Authors: Stein Moshe , Deitling Freddy , Cantor Angel , Perner Yvonne , Bezwoda Werner 
Published: February 2007

AbstractA 45‐year‐old black patient presented with right‐heart failure. Echocardiography showed a large tumor mass in the right atrium and a debulking procedure was performed. Histological and immunohistochemical studies revealed a high grade angiosarcoma infiltrating the myocardium and extending to the pericardial surface. Metastatic work‐up showed no evidence of dissemination. The patient made an uneventful postsurgical recovery and was treated with chemotherapy, consisting of epidoxorubicin and dacarbazin. Following chemotherapy, echocardiographic re‐evaluation failed to show any residual tumor in the right atrium.At present, one year following diagnosis, the patient is alive with no evidence of disease. Therapeutic options of primary cardiac angiosarcoma are reviewed. © 1994 Wiley‐Liss, Inc.
Primary osteosarcoma of the cervical spine: A pediatric case report and review of the literature
Authors: Kebudi Rejin , Ayan Inci , Darendeliler Emin , Aǧaoǧlu Leyla , Bayindir Çiçek , Turantan Inan , Kinay MÜNir , Bilge Nijad 
Published: February 2007

AbstractA 4 1/2‐year‐old girl with a primary osteosarcoma of the seventh cervical vertebra, treated by surgery and chemotherapy, and who is off therapy for 24 months with no evidence of disease is presented and the literature reviewed. © 1994 Wiley‐Liss, Inc.